Altogether, the present data provide the first evidence that the lncRNA SNHG5 has an oncogenic role in ccRCC through the SNHG5/miR‐205‐5p/ZEB1 signaling axis and represents a novel potential therapeutic regimen against ccRCC. Here, ZEB1 is linked to nonpapillary renal cell carcinoma.